Market capitalization | $187.76m |
Enterprise Value | $183.14m |
PER (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
P/B ratio (TTM) P/B ratio | 30.97 |
Sales growth (TTM) Sales growth | -100.00% |
Turnover (TTM) Turnover | $0.00 |
EBIT (operating result TTM) EBIT | $-36.50m |
Free cash flow (TTM) Free cash flow | $-32.19m |
As a Free StocksGuide user, you can view scores for all 6,945 stocks worldwide.
1 Analyst has issued a forecast Candel Therapeutics Inc:
1 Analyst has issued a forecast Candel Therapeutics Inc:
Dec '23 | |
Current assets | 37 37 |
Fixed assets | 4.91 4.91 |
Total assets | 42 42 |
Dec '23 | |
Equity | 13 13 |
Debt capital | 29 29 |
Total capital | 42 42 |
Figures in millions USD.
If you wish, you can receive an e-mail every morning in time for breakfast containing all the stock news relevant to you.
Candel Therapeutics, Inc. operates as a biopharmaceutical company that develops and commercializes cancer immunotherapy drugs. It offers aglatimagene besadenovec (CAN-2409), a replication-deficient adenovirus that delivers within infected cancer cells the herpes simplex virus thymidine kinase (HSV-tk) gene. The company was founded by Estuardo Aguilar-Cordova in 2002 and is headquartered in Needham, MA.
Head office | United States |
CEO | Paul-Peter Tak |
Employees | 42 |
Founded | 2002 |
Website | www.candeltx.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.